Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 162

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Ceftolozane/tazobactam for the treatment of serious Pseudomonas aeruginosa infections: a multicentre nationwide clinical experience

Open access
Bassetti, Matteo, Castaldo, Nadia, Cattelan, Annamaria, Mussini, Cristina, Righi, Elda, Tascini, Carlo, Menichetti, Francesco, Mastroianni, Claudio Maria, Tumbarello, Mario, Grossi, Paolo, Artioli, Stefania, Carannante, Novella, Cipriani, Ludovica, Coletto, Davide, Russo, Alessandro, Digaetano, Margherita, Losito, Angela Raffaella, Peghin, Maddalena, Capone, Alessandro, Nicolè, Stefano, Vena, Antonio, Bassetti, Matteo, Vena, Antonio, Castaldo, Nadia, Pecori, Davide, Righi, Elda, Carnellutti, Alessia, Givone, Filippo, Graziano, Elena, Merelli, Maria, Cadeo, Barbara, Peghin, Maddalena, Cattelan, Annamaria, Cipriani, Ludovica, Coletto, Davide, Mussini, Cristina, Digaetano, Margherita, Tascini, Carlo, Carannante, Novella, Menichetti, Francesco, Verdenelli, Stefano, Fabiani, Silvia, Mastroianni, Claudio Maria, Gianluca, Russo, Oliva, Alessandra, Ciardi, Maria Rosa, Ajassa, Camilla, Tieghi, Tiziana, Tumbarello, Mario, Losito, Angela Raffaella, Raffaelli, Francesca, Grossi, Paolo, Rovelli, Cristina, Artioli, Stefania, Caruana, Giorgia, Luzzati, Roberto, Bontempo, Giulia, Petrosillo, Nicola, Capone, Alessandro, Rizzardini, Giuliano, Coen, Massimo, Passerini, Matteo, Mastroianni, Antonio, Urso, Filippo, Bianco, Maria Francesca, Borgia, Guglielmo, Gentile, Ivan, Maraolo, Alberto Enrico, Crapis, Massimo, Venturini, Sergio, Parruti, Giustino, Trave, Francesca, Angarano, Gioacchino, Carbonara, Sergio, Mariani, Michele Fabiano, Girardis, Massimo, Cascio, Antonio, Gioé, Claudia, Anselmo, Marco, Malfatto, Emanuele·2019·International Journal of Antimicrobial Agents

Abstract

This study describes the largest clinical experience using ceftolozane/tazobactam (C/T) for different Pseudomonas aeruginosa infections. A retrospective study was performed at 22 hospitals in Italy (June 2016-March 2018). All adult patients treated with ≥4 days of C/T were enrolled. Successful clinical outcome was defined as complete resolution of clinical signs/symptoms related to P. aeruginosa infection and lack of microbiological evidence of infection. C/T treatment was documented in 101 patients with diverse infections, including nosocomial pneumonia (31.7%), acute bacterial skin and skin-structure infection (20.8%), complicated UTI (13.9%), complicated IAI (12.9%), bone infection (8.9%) and primary bacteraemia (5.9%). Over one-half of P. aeruginosa strains were XDR (50.5%), with 78.2% of isolates resistant to at least one carbapenem. C/T was used as first-line therapy in 39 patients (38.6%). When used as second-line or later, the most common reasons for discontinuation of previous antibiotics were in vitro resistance of P. aeruginosa and clinical failure of previous therapy. Concomitant antibiotics were reported in 35.6% of patients. C/T doses were 1.5 g q8h in 70 patients (69.3%) and 3 g q8h in 31 patients (30.7%); median duration of C/T therapy was 14 days. Overall clinical success was 83.2%. Significant lower success rates were observed in patients with sepsis or receiving continuous renal replacement therapy (CRRT). Mild adverse events were reported in only three patients. C/T demonstrated a favourable safety and tolerability profile regardless of the infection type. Clinicians should be aware of the risk of clinical failure with C/T therapy in septic patients receiving CRRT.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ijantimicag.2018.11.001

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 162

Metadata

Authors
Bassetti, M., Castaldo, N., Cattelan, A., Mussini, C., Righi, E., Tascini, C., Menichetti, F., Mastroianni, C. M., Tumbarello, M., Grossi, P., Artioli, S., Carannante, N., Cipriani, L., Coletto, D., Russo, A., Digaetano, M., Losito, A. R., Peghin, M., Capone, A., Nicolè, S., Vena, A., Bassetti, M., Vena, A., Castaldo, N., Pecori, D., Righi, E., Carnellutti, A., Givone, F., Graziano, E., Merelli, M., Cadeo, B., Peghin, M., Cattelan, A., Cipriani, L., Coletto, D., Mussini, C., Digaetano, M., Tascini, C., Carannante, N., Menichetti, F., Verdenelli, S., Fabiani, S., Mastroianni, C. M., Gianluca, R., Oliva, A., Ciardi, M. R., Ajassa, C., Tieghi, T., Tumbarello, M., Losito, A. R., Raffaelli, F., Grossi, P., Rovelli, C., Artioli, S., Caruana, G., Luzzati, R., Bontempo, G., Petrosillo, N., Capone, A., Rizzardini, G., Coen, M., Passerini, M., Mastroianni, A., Urso, F., Bianco, M. F., Borgia, G., Gentile, I., Maraolo, A. E., Crapis, M., Venturini, S., Parruti, G., Trave, F., Angarano, G., Carbonara, S., Mariani, M. F., Girardis, M., Cascio, A., Gioé, C., Anselmo, M., & Malfatto, E.
Venue
International Journal of Antimicrobial Agents
Publisher
Elsevier BV
Published
2019-04
Volume
53
Issue
4
Pages
408-415
ISSN
0924-8579 (ISSN-L)
OpenAlex
W2899536177
Cited by
162
References
2
FWCI
6.85
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Ceftolozane/tazobactam for the treatment of serious Pseudomonas aeruginosa infections: a multicentre nationwide clinical experience. https://app.cochat.ai/papers/10.1016/j.ijantimicag.2018.11.001
The paper
Bassetti, M., Castaldo, N., Cattelan, A., Mussini, C., Righi, E., Tascini, C., Menichetti, F., Mastroianni, C. M., Tumbarello, M., Grossi, P., Artioli, S., Carannante, N., Cipriani, L., Coletto, D., Russo, A., Digaetano, M., Losito, A. R., Peghin, M., Capone, A., . . . Malfatto, E. (2019). Ceftolozane/tazobactam for the treatment of serious Pseudomonas aeruginosa infections: a multicentre nationwide clinical experience. International Journal of Antimicrobial Agents. https://doi.org/10.1016/j.ijantimicag.2018.11.001

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.